LR-HEALTH-&-BEAUTY
7.6.2019 14:22:08 CEST | Business Wire | Press release
LR Health & Beauty has started a new beauty era this year with the LR LIFETAKT 5in1 Beauty Elixir. Four months after the market launch and a sensational amount of sold 2.6 million* shots, the revolutionary product was awarded the German Brand Award 2019 yesterday. In competition with "Excellent Brands", the Elixir impressed the top-ranking jury in the "Beauty & Care" category as one of the best product brands in the industry. In addition, the Elixir also received the "Special Mention" distinction in the cross-industry category "Product of the Year", which the jury awards for special aspects in branding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005247/en/
Andreas Friesch, CEO of LR Health & Beauty, is very proud of receiving this award. "Being the 'Winner' of the German Brand Award 2019 is a wonderful recognition for a very special product development. With the LR LIFETAKT 5in1 Beauty Elixir, we demonstrate our extensive health and beauty know-how in a single product. It is a reflection of our spectrum of competence and bears - like most of our products - the 'Made in Germany' seal of quality. Furthermore, the award is a motivation to continue developing pioneering innovations in the future as well.”
Excellent Beautyfood: LR LIFETAKT 5in1 Beauty Elixir
The most successful product launch in the history of the company, the LR LIFETAKT 5in1 Beauty Elixir fulfills five beauty wishes at once: youthful appearance, clear skin, firm body, healthy hair and strong nails. With just one shot a day, it ensures radiant beauty from head to toe – thanks to the unique double-complex with the most important active ingredients for beauty from science and from the power of nature. The 5in1 Beauty Elixir distinguishes itself from other beautyfood products on the market with the preventative complex that protects skin from the inside out from environmental factors and prevents the signs of ageing. Moreover, the active complex activates the beauty process in the body, ensuring radiant beauty from head to toe - no matter the age of the person using it. The Elixir has a fruity-fresh taste and is free of sweeteners, artificial colours, lactose and gluten.
The direct sales method with trained, independent sales partners who introduce and sell products in a professional manner with a high consultation level, is crucial to the success of the product.
German Brand Award | German Design Council
The German Brand Award is a prize offered by the German Design Council and the German Brand Institute, crowning the most innovative brands, consistent branding, and sustainable brand communication. It is divided into two competitions: "Excellent Brands" awards the best product and company brands in an industry. "Excellence in Brand Strategy and Creation" honours the strongest campaigns, concepts and strategies in individual disciplines.
The German Design Council is an independent and internationally active institution that assists companies to efficiently communicate design and brand competence, while at the same time aiming to strengthen the general public's understanding of design. Established as a foundation in 1953, at the initiative of the German Bundestag by the Federation of German Industries and several leading companies, the German Design Council supports the advancement of design and branding with its competitions, exhibitions, conferences, seminars and publications. Currently, over 300 companies both inland and abroad belong to the circle of founders of the German Design Council. More information: german-brand-award.com
LR Health & Beauty
With its "More quality for your life" campaign, the LR Group, with headquarters in Ahlen, Westphalia, produces and markets various beauty and health products in 28 countries. The products include care and decorative cosmetics, dietary supplements and perfume. The processing of aloe vera has been one of LR Health & Beauty's key areas of expertise for over 15 years, whereby the precious inside of the leaf is exclusively used. With an annual volume of 12,000 tons of aloe vera leaves, today the company is one of the largest manufacturers of aloe vera products worldwide. With 1,100 employees and thousands of registered Sales Partners and clients, LR is one of the leading direct sales companies in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005247/en/
Contact:
LR Health & Beauty Almut Kellermeyer Head of PR / Public Affairs Tel.: +49 2382 7060-106 E-mail: A.Kellermeyer@LRworld.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release
NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom